Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MindMaze Therapeutics HoldingRLFTY 11 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 75642.89% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
MindMaze Therapeutics Holding does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MindMaze Therapeutics Holding 3-Year ROIIC % Related Terms
MindMaze Therapeutics Holding 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RLFTY vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MindMaze Therapeutics Holding (RLFTY) has a 3-Year ROIIC % of 0.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1322 companies in the Biotechnology industry.
Is MindMaze Therapeutics Holding's 3-Year ROIIC % too high?
MindMaze Therapeutics Holding's current 3-Year ROIIC % is 0.00. Based on the distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1322 companies for 3-Year ROIIC %. This places MindMaze Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score
Get the complete analysis for RLFTY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLFTY has been successfully added to your 
